circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-15. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
His argument that future advanced systems may pose a threat to human existence prompted Elon Musk, Bill Gates, and Stephen Hawking to voice similar concerns. In 2015, dozens of artificial intelligence experts signed an open letter on artificial intelligence calling for research on the societal impacts of AI and outlining concrete directions. To date, the letter has been signed by over 8000 people including Yann LeCun, Shane Legg, Yoshua Bengio, and Stuart Russell. In the same year, a group of academics led by professor Stuart J. Russell founded the Center for Human-Compatible AI at the University of California Berkeley and the Future of Life Institute awarded $6.5 million in grants for research aimed at "ensuring artificial intelligence (AI) remains safe, ethical and beneficial". In 2016, the White House Office of Science and Technology Policy and Carnegie Mellon University announced The Public Workshop on Safety and Control for Artificial Intelligence, which was one of a sequence of four White House workshops aimed at investigating "the advantages and drawbacks" of AI. In the same year, Concrete Problems in AI Safety – one of the first and most influential technical AI Safety agendas – was published. In 2017, the Future of Life Institute sponsored the Asilomar Conference on Beneficial AI, where more than 100 thought leaders formulated principles for beneficial AI including "Race Avoidance: Teams developing AI systems should actively cooperate to avoid corner-cutting on safety standards".
=== Novels === Anecdotes persanes, dédiées au roy (1727 - English translation: Persian Anecdotes, dedicated to the King) Anecdotes, ou Histoire secrette de la maison ottomane (1722 - English translation: Anecdotes, or Secret History of the Ottoman House) Crémentine, reine de Sanga; histoire indienne (1727 - English translation: Creatine, Queen of Sanga: Indian History) Entretiens nocturnes de Mercure et de La Renommée, au jardin des Thuilleries (1714 - English translation: Nocturnal interviews of Mercury and La Renommée in the Tuileries Garden.) Histoire de Jean de Calais, roi de Portugal, ou, La vertu recompensee (1731 - English translation: The History of Jean de Calais, King of Portugal, or Virtue Rewarded) Histoire d'Osman premier du nom, XIXe empereur des Turcs, et de l'impératrice Aphendina Ashada (1734 - English translation: History of Osman, first of the name, XIXth emperor of the Turks, and of the empress Aphendina Ashada) Histoire du comte d’Oxfort, de Miledy d’Herby, d’Eustache de Saint-Pierre et de Beatrix de Guines au siège de la ville de Calais, sous le règne de Philippe de Valois, roi de France & de Navarré, en 1346 & 1347(1765 - English translation: History of the Count of Oxford, of Miledy of Herby, of Eustace of St. Peter and of Beatrix of Guines at the siege of the city of Calais, under the reign of Philip of Valois, King of France and of Navarre, in 1346 and 1347) Histoire secrette de la conqueste de Grenade (1723 - English translation: The secret history of the conquest of Granada) Histoires du comte d'Oxfort, de Miledy d'Herby, d'Eustache de S.
== Scope == Established in 1981, this facility is a National Science Foundation research facility. It is operated by both the Physics Department and the Geosciences Department of the University of Arizona. It is tasked with both scientific inquiry and education. Topical coverage of investigations includes archaeology, art history, forensic science, radioactive tracer studies, radiometric dating, the carbon cycle, cosmic ray physics, meteorites, geology, paleoclimate, faunal extinctions, hydrologic balance, frequency rate of forest fires, terrestrial magnetic field, solar wind, ocean sciences and instrument development.
Sources: en.wikipedia.org
Most atomic nuclei contain protons and neutrons. The number of protons determines the chemical element the nucleus belongs to. Different isotopes of the same element have different numbers of neutrons in their nuclei, but contain the same number of protons. For example, isotopes of carbon include carbon-12, carbon-13, carbon-14, which contain 6, 7, 8 neutrons respectively, but all contain 6 protons. Each isotope of an element has a different nuclear energy state, and may have different stability.
7-Fluorotryptamine (7-FT) is a serotonin receptor modulator and weak GPRC5A agonist of the tryptamine family. It is the 7-fluoro derivative of tryptamine. The drug is a low-potency agonist of the orphan receptor GPRC5A, with an EC50Tooltip half-maximal effective concentration of 7,200 nM. In addition to its GPRC5A agonism, 7-fluorotryptamine interacts with other receptors, such as the serotonin 5-HT4 receptor. Derivatives of 7-fluorotryptamine have been described. 7-Fluorotryptamine was first described in the scientific literature by 1979. Its GPRC5A agonism was first described in 2023. Substituted tryptamine 7-Chlorotryptamine 7-Methyltryptamine 7-Hydroxytryptamine 7-F-5-MeO-MET 7-Chloro-AMT 7-Fluorotryptamine - Isomer Design
James Rowley French (September 23, 1928 – December 20, 2017) was an American radio host, voice actor, writer and producer. French founded Imagination Theatre in 1996 and served as its producer until 2017. He was the morning DJ on the Seattle radio station KIRO from 1959 to 1971, and again from 1980 to 1994. As a voice actor, French was known for his work in video games by Valve, including Half-Life 2 (2004), Left 4 Dead (2008), and Dota 2 (2013).
Sources: en.wikipedia.org
== Further reading == Goel, Arun; Shrivastava, Prabhat (2010). "Post-burn scars and scar contractures". Indian Journal of Plastic Surgery. 43 (3). Georg Thieme Verlag KG: S63-71. doi:10.4103/0970-0358.70724. ISSN 0970-0358. PMC 3038392. PMID 21321660. Schneider, Jeffrey C.; Holavanahalli, Radha; Helm, Phala; Goldstein, Richard; Kowalske, Karen (2006). "Contractures in Burn Injury: Defining the Problem". Journal of Burn Care & Research. 27 (4). Oxford University Press (OUP): 508–514. doi:10.1097/01.bcr.0000225994.75744.9d. ISSN 1559-047X. PMID 16819356. S2CID 14982395.
The two substrates of this enzyme are (+)-cis-sabinol and oxidised nicotinamide adenine dinucleotide (NAD+. Its 3 products are (+)-sabinone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (+)-cis-sabinol:NAD+ oxidoreductase. This enzyme is also called (+)-cis-sabinol dehydrogenase.
== Suitability == As this method involves at least 2 rounds of washing, it may not be suitable for screening transient protein interactions, unlike the yeast two-hybrid method or in vivo crosslinking with photo-reactive amino acid analogs. However, it is a good method for testing stable protein interactions and allows various degrees of investigation by controlling the number of times the protein complex is purified.
William Dale Archerd (May 5, 1912 – October 29, 1977) was an American serial killer who killed at least three people with insulin injections between 1956 and 1966 in Northern California. He was the first to be convicted of using insulin as a murder weapon in the US, and he is suspected in three more cases.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.